Latest news and press releases about BridgeBio Oncology Therapeutics Inc. (BBOT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
Price
| Price | $4.76 |
| Market Cap | $381M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.00 |
| EV / EBITDA | -2.01 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -46.90% |
| Return on Invested Capital | -61.10% |
| Return on Assets | -48.34% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANAB · KOD · MNMD · NRIX · OCS · PHAT · SEPN
Explore sector: Healthcare · Biotechnology
More sections of BBOT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks